Deals: Page 50
-
Prescribed Reading: Bolt-on deals for Sanofi
The big pharma tries to fill its pipeline, Vertex touts strong CF data and the FDA gives three approvals.
By Lisa LaMotta • July 21, 2017 -
Exelixis and Genentech hammer out new deal terms
After a year of arbitration, the companies shook hands on a revised deal.
By Suzanne Elvidge • July 21, 2017 -
Courtesy of Sanofi
Sanofi inks immunology deal to expand pipeline
A small deal with Ablynx helps bolster Sanofi's pipeline as it rounds out its portfolio.
By Lisa LaMotta • July 20, 2017 -
Sarepta, BioMarin iron out Exondys 51 patent terms
The deal exchanges upfront, milestone and royalty payments for a patent estate covering exon-skipping therapies.
By Jacob Bell • July 18, 2017 -
Genentech BD: Alzheimer's continues to be a priority
Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease.
By Lisa LaMotta • July 17, 2017 -
Valeant unloads Obagi in latest sell-off
The beleaguered company continues to sell assets in an effort to reduce debt and move the company forward.
By Lisa LaMotta • July 17, 2017 -
BDSI inks Canadian marketing deal
BioDelivery Sciences and Purdue Pharma will be dancing cheek to cheek to launch BDSI's buccal buprenorphine in Canada.
By Suzanne Elvidge • July 17, 2017 -
Prescribed Reading: Rumors, blood and history in the making
Rumors swirl about a new CEO at Teva, hemophilia drugs are getting exciting and the first CAR-T therapy could be coming.
By Lisa LaMotta • July 14, 2017 -
Sunovion sheds asthma brands to focus on COPD
The Massachusetts drugmaker recently acquired rights to three COPD treatments from Novartis and hopes to soon win approval for its own developed therapy.
By Suzanne Elvidge • July 14, 2017 -
Elizabeth Regan/BioPharma Dive
Digital health funding hits record high in first half of 2017, Rock Health finds
Seven companies snared $100 million or more in funding during the second quarter.
By Meg Bryant • July 12, 2017 -
No game changer: Sanofi picks up flu vaccine
The French pharma is adding to its lofty vaccines portfolio with a quick bolt-on acquisition.
By Lisa LaMotta • July 11, 2017 -
Stada takeover: All over again?
After last month's unsuccessful takeover attempt, Bain Capital and Cinven have secured Stada's support for a revised bid.
By Suzanne Elvidge • July 11, 2017 -
Novartis hits pause on Fovista agreement
The Swiss drugmaker is no longer obligated to develop and commercialize Ophthotech's drug, at least until data from the OPH1004 study becomes available.
By Jacob Bell • July 10, 2017 -
J&J drops stem cell partner Capricor
Janssen Biotech's decision not to exercise an option for a cardiology candidate has batted Capricor stock.
By Suzanne Elvidge • July 10, 2017 -
Prescribed Reading: I/O is the only game in town
Immuno-oncology dominates dealmaking, clinical trial data and regulatory action.
By Lisa LaMotta • July 7, 2017 -
Acer aims for public listing through reverse merger
Struggling biotech Opexa gets a lift for shareholders as Acer takes over its shell.
By Suzanne Elvidge • July 7, 2017 -
Konica Minolta buys US genetic test maker in $1B deal
The Japanese imaging firm aims to play a bigger role in precision medicine and adding Ambry Genetics will give it the genetic testing capabilities it needs.
By Suzanne Elvidge • July 7, 2017 -
Celgene makes play to strengthen PD-1 position
The big biotech is buying its way further into the PD-1 race through a deal with China's BeiGene.
By Lisa LaMotta • July 6, 2017 -
Oxford BioMedica, Novartis link up on CAR-T drug production
The deal could provide more than $100 million to the U.K.-based gene therapy developer as well as long-term profitability, according to analysts.
By Jacob Bell • July 6, 2017 -
Roche snaps up diabetes startup mySugr
MySugr recently recorded its one millionth registered user on its digital diabetes management platform.
By Suzanne Elvidge • July 5, 2017 -
Prescribed Reading: Gottlieb pushes for efficiency at FDA
The Chief is trying to fulfill promises, while deal activity continues to stagnate in the sector as the industry waits on news from Washington.
By Lisa LaMotta • June 30, 2017 -
Prescribed Reading: What we know from BIO
A closer look at the trends everyone was talking about at BIO, FDA continues its approval spree and Novartis has heart.
By Lisa LaMotta • June 23, 2017 -
Cell Medica boosts manufacturing capacity in cell therapy deal
The U.K. cell therapy company hopes to push forward with development of CGT Catapult's WT1 targeting T-cell receptor technology.
By Suzanne Elvidge • June 21, 2017 -
Pricing pressures lower drug sales forecasts, new report finds
It was the first lowering of long-term sales expectations in the 10-year history of EvaluatePharma's World Preview reports.
By Jacob Bell • June 21, 2017 -
Report: Biopharma dealmaking set to level off
A new survey from InVentiv Health suggests 2017 may see M&A levels closer to recent historical norms rather than the peak seen in 2015.
By Ned Pagliarulo • June 21, 2017
Previous
